Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 12, 2024 | June 14, 2024 |
| Fresh Tracks Therapeutics, Inc.BBI · Entity 90076 | Director · CHIEF EXECUTIVE OFFICER | February 14, 2020 | February 19, 2020 |
| Innoviva, Inc.INVA · Entity 4679 | Sr. VP & Chief Comm. Officer | August 20, 2018 | August 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,431 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 6,820 · Balance 36,431 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.30 · Expires 2034-06-12 | Direct | 49,933 |
Reported balance
After 2024-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-12 · Grant · Acquired 49,933 · Balance 49,933 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Fresh Tracks Therapeutics, Inc.
Report date February 14, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2030-02-13 | Direct | 2,167 |
Reported balance
After 2020-02-14 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-02-14 · Grant · Acquired 2,167 · Balance 2,167 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2030-02-13 | Direct | 8,764 |
Reported balance
After 2020-02-14 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-02-14 · Grant · Acquired 8,764 · Balance 8,764 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2021-01-25 | Direct | 8,630 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 8,630 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.37 · Expires 2024-02-22 | Direct | 2,589 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 2,589 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $12.17 · Expires 2025-04-22 | Direct | 8,630 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 8,630 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $12.17 · Expires 2026-12-15 | Direct | 3,452 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 3,452 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2028-12-15 | Direct | 5,178 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 5,178 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.76 · Expires 2029-08-30 | Direct | 34,521 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 34,521 |
| Common StockSEC Table I · non-derivative | Direct | 7,230 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,230 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse as Trustee | 12,082 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,082 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse as Trustee | 12,082 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 12,082 |
| Common StockSEC Table I · non-derivative | IndirectBy Self as Trustee | 107,030 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 107,030 |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $10.36 · Expires 2019-08-30 | Direct | 3,316 |
Reported balance
Holding disclosure · report date 2020-02-14 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,316 |
Innoviva, Inc.
Report date August 20, 2018 · Filed August 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 285,479 |
Ending reported balance
After 2018-08-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-08-20 · Tax withholding · Disposed 5,680 · Balance 293,479 F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Row 2 · 2018-08-21 · Sale · Disposed 8,000 · Balance 285,479 F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2017. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.9100 to $14.1950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2017.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.9100 to $14.1950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2024 Filed Jun 14, 2024 20:18 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 49,933 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001127602-24-018705 · form4.xml · derivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,933 Underlying: Common Stock · 49,933 shares Expires 2034-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:18 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 6,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018705 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,431 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:28 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 39,072 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001127602-23-018765 · form4.xml · derivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,072 Underlying: Common Stock · 39,072 shares Expires 2033-06-13 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:28 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 16,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018765 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,611 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,022 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001127602-22-017153 · form4.xml · derivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017153 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,866 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 5,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001127602-22-012272 · form4.xml · derivative · entry 3 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F2 · derivative.exercise_date: The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 5,000 | $11.04 | $55,200.00 |
DisclosureSEC source: 0001127602-22-012272 · form4.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 5,000 | $3.32 | $16,600.00 |
DisclosureSEC source: 0001127602-22-012272 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 5,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001127602-22-005295 · form4.xml · derivative · entry 3 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F3 · derivative.exercise_date: The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 5,000 | $18.50 | $92,500.00 |
DisclosureSEC source: 0001127602-22-005295 · form4.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.00 to $18.76. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 5,000 | $3.32 | $16,600.00 |
DisclosureSEC source: 0001127602-22-005295 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:27 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 5,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001127602-21-029440 · form4.xml · derivative · entry 3 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F3 · derivative.exercise_date: The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:27 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 5,000 | $12.27 | $61,350.00 |
DisclosureSEC source: 0001127602-21-029440 · form4.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.22 to $12.29. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:27 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 5,000 | $3.32 | $16,600.00 |
DisclosureSEC source: 0001127602-21-029440 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001127602-21-025496 · form4.xml · derivative · entry 3 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F3 · derivative.exercise_date: The option vested 1/8 per month for a period of 8 months, beginning on October 10, 2011. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 5,000 | $15.06 | $75,300.00 |
DisclosureSEC source: 0001127602-21-025496 · form4.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $14.90 to $15.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 5,000 | $2.63 | $13,150.00 |
DisclosureSEC source: 0001127602-21-025496 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001127602-21-025252 · form4.xml · derivative · entry 7 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-21-025252 · form4.xml · derivative · entry 6 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 11,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001127602-21-025252 · form4.xml · derivative · entry 5 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 74,000 | $15.09 | $1,116,660.00 |
DisclosureSEC source: 0001127602-21-025252 · form4.xml · nonDerivative · entry 4 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $14.87 to $15.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 30,000 | $2.91 | $87,300.00 |
DisclosureSEC source: 0001127602-21-025252 · form4.xml · nonDerivative · entry 3 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 30,000 | $3.22 | $96,600.00 |
DisclosureSEC source: 0001127602-21-025252 · form4.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 11,000 | $1.71 | $18,810.00 |
DisclosureSEC source: 0001127602-21-025252 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:39 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001127602-21-022226 · form4.xml · derivative · entry 3 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2021-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F3 · derivative.exercise_date: The option vested 1/8 per month for a period of 8 months, beginning on October 10, 2011. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:39 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 5,000 | $15.69 | $78,450.00 |
DisclosureSEC source: 0001127602-21-022226 · form4.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.46 to $16.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:39 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 5,000 | $2.63 | $13,150.00 |
DisclosureSEC source: 0001127602-21-022226 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0001127602-21-018171 · form4.xml · derivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionNon-Qualified Stock Option · Derivative | 6,667 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001127602-21-018061 · form4.xml · derivative · entry 3 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 6,667 shares Expires 2021-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F3 · derivative.exercise_date: The option vested 1/8 per month for a period of 8 months, beginning on October 10, 2011. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 6,667 | $13.90 | $92,671.30 |
DisclosureSEC source: 0001127602-21-018061 · form4.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.77 to $14.11. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 6,667 | $2.63 | $17,534.21 |
DisclosureSEC source: 0001127602-21-018061 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| May 10, 2021 Filed May 12, 2021 21:02 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 7,000 | $12.70 | $88,900.00 |
DisclosureSEC source: 0001127602-21-016433 · form4.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.69 to $12.72. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001127602-20-016548 · form4.xml · derivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 17:07 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantStock Options · Derivative | 8,764 | $1.16 Strike: $1.16 | $10,166.24 |
DisclosureSEC source: 0001214659-20-001606 · marketforms-47805.xml · derivative · entry 13 ABERCROMBIE GEORGE B · CIK 0001485939 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,764 Underlying: Common Stock · 8,764 shares Expires 2030-02-13 Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 17:07 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantRestricted Stock Units · Derivative | 2,167 | $1.16 Strike: $1.16 | $2,513.72 |
DisclosureSEC source: 0001214659-20-001606 · marketforms-47805.xml · derivative · entry 12 ABERCROMBIE GEORGE B · CIK 0001485939 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,167 Underlying: Common Stock · 2,167 shares Expires 2030-02-13 Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:10 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001127602-19-020298 · form4.xml · derivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| August 21, 2018 Filed Aug 22, 2018 22:46 UTC | Innoviva, Inc. INVA · Entity 4679 | SaleCommon Stock | 8,000 | $14.11 | $112,840.00 |
DisclosureSEC source: 0001567619-18-001672 · doc1.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,479 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.9100 to $14.1950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 22:46 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 5,680 | $14.08 | $79,974.40 |
DisclosureSEC source: 0001567619-18-001672 · doc1.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,479 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 13:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001127602-18-021724 · form4.xml · derivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-20 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning July 20, 2018. Read SEC document |
| May 21, 2018 Filed May 22, 2018 23:52 UTC | Innoviva, Inc. INVA · Entity 4679 | SaleCommon Stock | 8,000 | $14.40 | $115,202.40 |
DisclosureSEC source: 0001179110-18-007382 · edgar.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,159 F2 · shares: This sale was effected for tax planning purposes. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.31 to $14.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · balance_after: Includes 1,924 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 15, 2018. Read SEC document |
| May 20, 2018 Filed May 22, 2018 23:52 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 4,682 | $14.59 | $68,310.38 |
DisclosureSEC source: 0001179110-18-007382 · edgar.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,235 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 21:14 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 74,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003602 · edgar.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,917 F1 · shares: Includes 24,814 shares of common stock granted pursuant to a time-based restricted stock award (RSA). Twenty-five percent of the shares subject to the RSA shall vest on February 20, 2019, and 6.25% of the shares subject to the RSA shall vest quarterly thereafter on the Issuer's standard vesting dates until February 20, 2022, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · shares: Includes shares of common stock granted pursuant to a performance-based restricted stock award (PSA). The shares vest pursuant to the PSA over a three-year period upon, and subject to a formula related to, the Issuer's achievement of certain levels of relative total shareholder return (TSR). The "target" number of shares that may vest is 24,815, but the actual number of shares that may vest will range from 0 to 49,630 shares based on the Issuer's relative TSR over the performance period. Subject to achievement of the performance-based vesting conditions, the shares eligible to vest based on achievement will vest on February 20, 2021 provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 21:23 UTC | Innoviva, Inc. INVA · Entity 4679 | SaleCommon Stock | 8,000 | $16.51 | $132,100.00 |
DisclosureSEC source: 0001179110-18-002588 · edgar.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,473 F2 · shares: This sale was effected for tax planning purposes pursuant to the Reporting Person's Rule 10b5-1 Trading Plan dated September 20, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.31 to $16.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · balance_after: Includes 322 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on November 15, 2017. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:23 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 15,500 | $16.44 | $254,820.00 |
DisclosureSEC source: 0001179110-18-002588 · edgar.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,473 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| November 21, 2017 Filed Nov 22, 2017 21:52 UTC | Innoviva, Inc. INVA · Entity 4679 | SaleCommon Stock | 5,215 | $13.26 | $69,145.16 |
DisclosureSEC source: 0001179110-17-014574 · edgar.xml · nonDerivative · entry 2 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,651 F2 · shares: This sale was effected for tax planning purposes pursuant to the Reporting Person's Rule 10b5-1 Trading Plan dated September 20, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.21 to $13.395, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 21:52 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 3,358 | $13.17 | $44,224.86 |
DisclosureSEC source: 0001179110-17-014574 · edgar.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,866 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| August 20, 2017 Filed Aug 22, 2017 20:38 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 2,886 | $12.28 | $35,440.08 |
DisclosureSEC source: 0001179110-17-011732 · edgar.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,224 F1 · shares: The shares were withheld by the Company to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:37 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019325 · form4.xml · derivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| May 20, 2017 Filed May 23, 2017 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 2,228 | $11.86 | $26,424.08 |
DisclosureSEC source: 0001179110-17-007831 · edgar.xml · nonDerivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Sr. VP & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,110 F1 · shares: These shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards. F2 · balance_after: Includes 2,500 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.